Redeye comments on the better-indicated momentum for Carbonhand in Germany.
Redeye sees continued solid growth momentum and impressive gross margins, partly thanks to surprisin...
Redeye provides its initial take on Vitec’s Q3 2023 report, which came in roughly in line with our e...
Sales -6% and adj. EBIT SEK +0.5m vs. ABGSCe Outlook largely unchanged as the company recovers from ...
Consti reports its Q3 results on 27th of October. We expect continued good execution supported by th...
Q3e: Two Freemelt ONE deliveries, sales SEK 10.3m, up 28% y-o-y First eMELT agreement with large glo...
iZafe vinner en upphandling med Västra Götalandsregionen för tillhandahållande av omkring 2000 Dosel...
Redeye shares its preview of Sedana Medical’s Q3 2023e results, due October 26.
OrderYOYO announced on Wednesday, October 18th, the company’s performance during Q3-23 and shows a c...
Expect a great Q3e: sales SEK 44m, up 46% y-o-y; 46% EBIT margin We raise '23e-'24e EBIT 7-4% on ann...
Redeye shares its preview of BONESUPPORT’s Q3 2023e results, due October 26.
MT Højgaard announces win of Rønne harbour phases 3 and 4No order amount included in Tuesdays press ...
RanLOS AB (publ) (”RanLOS” eller ”Bolaget”) utvecklar och säljer en nyckelfärdig lösning inom testni...
Finnair reports Q3 results on Oct 24. We make some downward revisions to our estimates, but note ear...
Redeye provides a brief initial take on Ultimovacs reporting more granular NIPU data.
Redeye endorses Circio’s implementation of the cost reduction program, which will extend its runway.
CMD in Stockholm focused on mesdopetam Potential Ph 3 programme outlined by KOL End-of-phase 2 meeti...
Redeye participated during yesterday’s capital markets day and give an initial comment.
Redeye provides an update on Fantasma Games ahead of its Q3 results (due 8 Nov).
Elanders presented a somewhat soft Q3 2023 report with -11% organic growth, owing to Supply Chain So...
